• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Barinthus Biotherapeutics plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/10/25 4:05:30 PM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BRNS alert in real time by email
    false 0001828185 0001828185 2025-06-10 2025-06-10 0001828185 VACC:AmericanDepositarySharesMember 2025-06-10 2025-06-10 0001828185 us-gaap:CommonStockMember 2025-06-10 2025-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 10, 2025

     

    BARINTHUS BIOTHERAPEUTICS PLC

    (Exact name of registrant as specified in its charter)

     

    England and Wales 001-40367 Not Applicable

    (State or other jurisdiction

    of incorporation)

    (Commission

    File Number)

    (I.R.S. Employer

    Identification No.)

     

    Barinthus Biotherapeutics plc

    Unit 6-10, Zeus Building Rutherford Avenue,

    Harwell, Didcot, OX11 0DF

    United Kingdom

    (Address of principal executive offices, including zip code)

     

    +44 (0) 1865 818 808

    (Registrant’s telephone number, including area code)

     

    Not Applicable 

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trade Symbol(s) Name of each exchange on which
    registered
    American Depositary Shares BRNS The Nasdaq Global Market
    Ordinary shares, nominal value £0.000025 per share*    

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company  x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

     

    *American Depositary Shares may be evidenced by American Depositary Receipts. Each American Depositary Share represents one (1) ordinary share. Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8.

     

     

    00-0000000

     

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    On June 10, 2025, Barinthus Biotherapeutics plc (the “Company”) held its 2025 Annual General Meeting (the “Annual General Meeting”). Proxies were solicited pursuant to the Company’s definitive proxy statement filed on April 25, 2025 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended. The number of shares of ordinary shares, nominal value £0.000025 per share, of the Company (the “Ordinary Shares”) entitled to vote at the Annual Meeting was 40,339,395. The number of shares of Ordinary Shares present or represented by valid proxy at the Annual Meeting was 26,993,016, thus establishing a quorum for the Annual Meeting. All matters submitted to a vote of the Company’s stockholders at the Annual Meeting were approved and the director nominees were elected. The voting results reported below are final.

     

    Ordinary Resolutions   For   Against   Withheld   Broker Non-Votes
    To re-elect as a director, Pierre A. Morgon, who retires by rotation in accordance with the Company’s Articles of Association.   23,310,721   265,820   254   3,416,221
    To re-elect as a director, Joseph C. Scheeren, who retires by rotation in accordance with the Company’s Articles of Association.   23,329,772   246,769   254   3,416,221
    To re-appoint PricewaterhouseCoopers LLP, as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders.   26,887,808   3,311   101,895   2
    To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.   26,887,933   3,186   101,895   2
    To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2025.   26,985,442   6,782   791   1
    To receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2024 and to note that the Company's directors do not recommend the payment of any dividend for the fiscal year ended December 31, 2024.   26,983,943   5,132   3,941   0
    To approve the Company's directors' remuneration policy.   23,535,233   34,344   7,228   3,416,211
    To receive and approve on an advisory basis the Company's U.K. statutory directors' compensation report for the fiscal year ended December 31, 2024.   23,557,140   16,651   4,029   3,415,196

     

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Barinthus Biotherapeutics plc
         
    Date: June 10, 2025 By: /s/ William Enright
        William Enright
        Chief Executive Officer

     

     

     

    Get the next $BRNS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BRNS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BRNS
    SEC Filings

    See more
    • Barinthus Biotherapeutics plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)

      6/10/25 4:05:30 PM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Barinthus Biotherapeutics plc

      10-Q - Barinthus Biotherapeutics plc. (0001828185) (Filer)

      5/7/25 8:12:43 AM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barinthus Biotherapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)

      5/7/25 8:10:46 AM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BRNS
    Leadership Updates

    Live Leadership Updates

    See more
    • Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

      OXFORD, United Kingdom and GERMANTOWN, Md., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio"), today announced the promotion of Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer (CSO), effective as of December 1, 2024. Dr. Lynn succeeds Nadège Pelletier, Ph.D. who decided to pursue alternative opportunities closer to home after having served as Barinthus Bio's CSO since early 2023. Barinthus Bio is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease. "Dr. Pelletier's strong vision and leadership have resulted in a robust preclinical pipeline of promising leads for

      11/25/24 4:01:00 PM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer

      OXFORD, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc, a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, today announced the appointment of Leon Hooftman, M.D., as Chief Medical Officer (CMO). "We are happy to welcome Dr. Hooftman to Barinthus Bio as our Chief Medical Officer. With his experience spearheading clinical studies from early development through late-stage trials, he is a valuable addition to the Barinthus Bio team during a critical time in our growth," said Chi

      5/1/24 7:00:00 AM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BRNS
    Financials

    Live finance-specific insights

    See more
    • Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments

      Highly differentiated immunotherapy for celiac disease (VTP-1000) in the clinic, with Phase 1 single ascending dose readout from AVALON expected in the third quarter of 2025;Initiation of VTP-1000 multiple ascending dose expected in the second half of 2025; Encouraging results from HBV003 and IM-PROVE II presented at EASL, supporting ongoing partnering efforts; Available resources expected to provide a cash runway into 2027. OXFORD, United Kingdom and GERMANTOWN, Md., May 07, 2025 (GLOBE NEWSWIRE) --  Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation ("I&I") company focused on developing therapies that promote immune tolerance

      5/7/25 8:00:00 AM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments

      Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative immunotherapy for celiac disease (VTP-1000) in the clinic, with first data expected in third quarter of 2025Proprietary SNAP-TI platform promoting antigen-specific immune tolerance is anticipated to drive multiple future pipeline and partnership opportunities Strategic prioritization of resources expected to provide a cash runway into 2027 OXFORD, United Kingdom and GERMANTOWN, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation (I&

      3/20/25 7:22:19 AM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results

      OXFORD, United Kingdom, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates, provided an overview of the Company's progress and announced its financial results for the second quarter of 2024. "Following the positive VTP-300 Phase 2 data in hepatitis B virus (HBV) in the second quarter, we made the strategic decision to prioritize our HBV and celiac disease programs. These two programs have the greatest probability for success and value creation, and represent significant opportunities in therapeutic areas with substantial unmet patient need," said Bill Enright, Chief

      8/8/24 8:00:00 AM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BRNS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Barinthus Biotherapeutics plc

      SC 13G/A - Barinthus Biotherapeutics plc. (0001828185) (Subject)

      11/1/24 11:20:26 AM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Barinthus Biotherapeutics plc

      SC 13G - Barinthus Biotherapeutics plc. (0001828185) (Subject)

      10/15/24 11:07:21 AM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BRNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Hammacher Alex

      4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)

      6/11/25 5:18:30 PM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Wright Robin

      4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)

      6/11/25 5:17:38 PM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Morgon Pierre A.

      4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)

      6/11/25 5:16:31 PM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BRNS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments

      Highly differentiated immunotherapy for celiac disease (VTP-1000) in the clinic, with Phase 1 single ascending dose readout from AVALON expected in the third quarter of 2025;Initiation of VTP-1000 multiple ascending dose expected in the second half of 2025; Encouraging results from HBV003 and IM-PROVE II presented at EASL, supporting ongoing partnering efforts; Available resources expected to provide a cash runway into 2027. OXFORD, United Kingdom and GERMANTOWN, Md., May 07, 2025 (GLOBE NEWSWIRE) --  Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation ("I&I") company focused on developing therapies that promote immune tolerance

      5/7/25 8:00:00 AM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments

      Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative immunotherapy for celiac disease (VTP-1000) in the clinic, with first data expected in third quarter of 2025Proprietary SNAP-TI platform promoting antigen-specific immune tolerance is anticipated to drive multiple future pipeline and partnership opportunities Strategic prioritization of resources expected to provide a cash runway into 2027 OXFORD, United Kingdom and GERMANTOWN, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation (I&

      3/20/25 7:22:19 AM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

      Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is identifiedExtending the cash runway to the start of 2027 by reducing costs, including an approximate 65% reduction in workforce and expected closure of the U.K. site Future operations will be focused at the U.S. site in Germantown, Maryland OXFORD, United Kingdom and GERMANTOWN, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), today provided a strategic business and financial update. Barinthus Bio is a clinical-stage biopharmaceutical co

      1/10/25 8:00:00 AM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care